Tirzepatide

Tirzepatide is a synthetic peptide that activates two incretin receptors at once — the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is an approved medicine, sold by Eli Lilly as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and, since December 2024, moderate to severe obstructive sleep apnea in adults with obesity.

What makes tirzepatide notable is not that it is another incretin drug, but that it was the first to show a second incretin receptor adds real clinical effect. In the SURMOUNT-1 obesity trial (n=2,539), the 15 mg dose produced a mean weight reduction of 20.9% over 72 weeks versus 3.1% with placebo (Jastreboff et al., NEJM 2022) — a larger effect than any previously approved obesity medication had shown — and in SURPASS-2 it beat semaglutide 1 mg head-to-head on both blood glucose and weight (Frías et al., NEJM 2021).

Incretins are gut hormones released after eating. The two main ones, GIP and GLP-1, signal the pancreas to release insulin when glucose is high and help regulate appetite. Most drugs in this class — semaglutide, liraglutide, dulaglutide — mimic GLP-1 only. Tirzepatide is engineered differently: the molecule is based on the native GIP sequence, modified so that it also activates the GLP-1 receptor, with a C20 fatty diacid attached that binds albumin in the blood and stretches the half-life to roughly 5 days (Zepbound label, DailyMed).

The two receptors contribute distinct effects:

• GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite and caloric intake.

• GIP receptor activation is also insulinotropic, and nonclinical studies suggest it adds further regulation of food intake on top of GLP-1 signaling.

In the discovery program, experiments in receptor-knockout mice showed the compound's glucose effects required both receptors — it behaves as a true dual agonist rather than a GLP-1 drug with a passenger sequence, and its glucose and weight effects exceeded those of selective GLP-1 agonists from preclinical work through early human studies (Coskun et al., Molecular Metabolism 2018). This dual mechanism is the main hypothesis for why tirzepatide outperformed semaglutide 1 mg in direct comparison, though exactly how much GIP contributes in humans is still debated.

The same molecule is approved under two brand names with different labels:

• Mounjaro (approved May 2022) — an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (Mounjaro label, DailyMed).

• Zepbound (approved November 2023) — chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and exercise. In December 2024 the FDA extended the label to moderate to severe obstructive sleep apnea in adults with obesity — the first medication ever approved for OSA (FDA press announcement, Dec 2024).

These approvals apply to the manufactured pharmaceutical products dispensed by prescription. Vials sold by peptide vendors as "research use only" tirzepatide are not the approved medicine, are not manufactured or verified to pharmaceutical standards, and sit outside this regulatory framework — a distinction that matters more here than for most compounds on this site, because demand for the branded products has pushed a large gray market into existence.

Because tirzepatide is an approved drug, its adverse-effect profile is far better characterized than that of most peptides. The most common adverse reactions, reported in at least 5% of treated patients, are gastrointestinal: nausea, diarrhea, vomiting, constipation, dyspepsia, decreased appetite, and abdominal pain; the Zepbound label additionally lists injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, and gastroesophageal reflux (Zepbound label). In SURMOUNT-1, gastrointestinal events were the most common adverse events, occurred mainly during dose escalation, and were mostly mild to moderate (Jastreboff et al. 2022).

The labeling carries a boxed warning for thyroid C-cell tumors: tirzepatide caused these tumors in rats at clinically relevant exposures, and while human relevance is undetermined, the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (Mounjaro label). Other labeled warnings include:

• Acute pancreatitis.
• Gallbladder disease (cholelithiasis, cholecystitis).
• Hypoglycemia when combined with insulin or insulin secretagogues such as sulfonylureas.
• Acute kidney injury from volume depletion after severe vomiting or diarrhea.
• Worsening of diabetic retinopathy in patients with a history of it (Mounjaro label).
• Slowed gastric emptying, which can alter absorption of oral medications and has led to anesthesia guidance about pausing incretin drugs before planned procedures.

Tirzepatide is given as a once-weekly subcutaneous injection. The C20 fatty diacid modification binds albumin, producing a half-life of about 5 days — long enough that steady weekly dosing maintains continuous receptor exposure, and long enough that effects persist for days after a missed or final dose.

One pharmacological point with practical weight: tirzepatide treats rather than cures the underlying biology. In the SURMOUNT-4 withdrawal trial, participants who lost 20.9% of body weight in a 36-week lead-in and were then switched to placebo regained most of it (+14.0% over the following year), while those who continued lost a further 5.5% (Aronne et al., JAMA 2024). See the dosing education page for a fuller discussion of how the labels structure treatment.

The approved products are supplied as single-dose prefilled pens and single-dose vials in six strengths from 2.5 mg to 15 mg (each in 0.5 mL), plus a multi-dose KwikPen presentation. Mounjaro and Zepbound are the same molecule at the same strengths; the two brands exist because diabetes and obesity are regulated, prescribed, and reimbursed as separate indications.

Combination use is constrained by the labeling: coadministration with any GLP-1 receptor agonist or other tirzepatide-containing product is not recommended, and pairing with insulin or sulfonylureas raises hypoglycemia risk that typically prompts dose reductions of those drugs (Zepbound label).

Within the incretin class, tirzepatide sits between semaglutide (GLP-1 receptor only) and retatrutide (an investigational triple agonist that adds glucagon-receptor activity). For direct head-to-head breakdowns, see semaglutide vs tirzepatide and tirzepatide vs retatrutide.

Tirzepatide's evidence base comes from two large phase 3 programs plus follow-on studies:

• SURPASS (type 2 diabetes). In SURPASS-2 (n=1,879), tirzepatide 5/10/15 mg lowered HbA1c by 2.01–2.30 percentage points versus 1.86 for semaglutide 1 mg, with 1.9–5.5 kg more weight loss — superiority at every dose (Frías et al., NEJM 2021).

• SURMOUNT-1 (obesity, n=2,539). Mean weight change at 72 weeks: −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) versus −3.1% with placebo; 57% of the 15 mg group lost at least 20% of body weight (Jastreboff et al., NEJM 2022).

• SURMOUNT-4 (withdrawal design, n=670 randomized). Continuing tirzepatide after initial loss led to a total 25.3% reduction by week 88; switching to placebo led to substantial regain (Aronne et al., JAMA 2024).

• Body composition. In a SURMOUNT-1 DXA substudy (n=160), about 75% of weight lost was fat mass and 25% lean mass — the same ratio seen with placebo weight loss (Look et al., Diabetes Obes Metab 2025).

• SURMOUNT-OSA (sleep apnea). Across two phase 3 trials, tirzepatide reduced the apnea–hypopnea index by 25–29 events per hour versus about 5 with placebo, supporting the December 2024 OSA approval (Malhotra et al., NEJM 2024).

Ongoing work includes cardiovascular-outcome and kidney research, heart failure with preserved ejection fraction, and metabolic liver disease. The research and evidence page covers the program in more depth.

For deeper dives on this peptide, see:

• Tirzepatide benefits and areas of interest
• Tirzepatide side effects and safety context
• Tirzepatide dosing concepts (educational)
• Tirzepatide research and evidence overview

How is tirzepatide different from a GLP-1 agonist like semaglutide? Tirzepatide is a dual agonist: it activates the GIP receptor in addition to the GLP-1 receptor, whereas semaglutide acts on the GLP-1 receptor alone. In the only completed head-to-head trial, SURPASS-2, tirzepatide produced greater HbA1c and weight reductions than semaglutide 1 mg at all three doses (NEJM 2021), though that trial used semaglutide's diabetes dose, not the higher 2.4 mg obesity dose. See the full comparison page.

Is tirzepatide an approved medicine? Yes. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and moderate to severe obstructive sleep apnea in adults with obesity. Approved indications, eligibility criteria, and dosing schedules are set by the product labeling in each jurisdiction — and none of them extend to "research use only" vials sold outside the pharmacy system.

How much weight did people lose in trials? In SURMOUNT-1, average loss at 72 weeks was 15.0% to 20.9% of body weight depending on dose, versus 3.1% with placebo, with over half of the highest-dose group losing at least 20% (NEJM 2022). Trial participants also received diet and lifestyle support, so these are best-case structured-care numbers, not a guarantee.

Do you regain the weight after stopping? Largely, yes. In SURMOUNT-4, participants switched to placebo after nine months of treatment regained an average of 14.0% of body weight over the following year, while those who continued kept losing (JAMA 2024). Obesity medicine increasingly treats this as evidence the drug manages a chronic condition rather than curing it.

Does tirzepatide cause muscle loss? Some lean mass goes down with any substantial weight loss. In the SURMOUNT-1 DXA substudy, roughly 75% of weight lost on tirzepatide was fat and 25% was lean mass — the same proportion as in placebo participants who lost weight (Diabetes Obes Metab 2025). Whether that lean-mass change matters functionally is an open research question; see can weight-loss peptides affect muscle mass.

Why is tirzepatide dosed with a gradual titration? Gastrointestinal side effects such as nausea are dose-related, so the labeled regimens start at a low 2.5 mg weekly dose and step up no faster than every 4 weeks to improve tolerability. How far titration proceeds, and at what pace, is a clinical decision made with a prescriber.

How does tirzepatide compare to retatrutide? Retatrutide adds a third mechanism — glucagon-receptor agonism — on top of GIP and GLP-1, and produced larger phase 2 weight reductions, but it remains investigational with no approved indication, while tirzepatide has completed phase 3 programs and carries full regulatory approval. See tirzepatide vs retatrutide.